Innovative Vaccine BOPRIVA

Management of reproductive function and behavior in cattle is a key factor in the efficiency of livestock enterprises. Traditional castration methods are often associated with significant stress for animals and a risk of complications. The BOPRIVA vaccine developed by Zoetis offers a modern and humane solution: it stimulates the production of antibodies against endogenous gonadotropin-releasing hormone (GnRH), leading to the natural suppression of sexual activity. This allows effective control of testosterone levels in bulls and progesterone levels in heifers without surgical intervention.

The main advantage of BOPRIVA for large farms is the significant improvement of the production environment. Vaccination greatly reduces aggressive behavior and unwanted sexual activity for a period of 12 to 20 weeks. This simplifies herd management, reduces the risk of injuries among animals and staff, and promotes calmer weight gain. The product is administered subcutaneously at a dose of 1 ml and begins to act within 7–14 days after the second injection.

Introducing BOPRIVA into the technological cycle of your enterprise is an investment in biosecurity and animal welfare. The product does not contain hormones or GMOs, and meat from vaccinated cattle is completely safe for consumers, confirmed by the absence of a withdrawal period before slaughter. The use of BOPRIVA helps optimize workflows, improve product quality, and strengthen the reputation of your business as a modern and responsible producer.